Valeant had seen some modestly good news heading into earnings. The company paid down debt early after an asset sale to L'Oreal SA (ADR) (OTCMKTS: LRLCY ) closed ahead of schedule. The launch of psoriasis drug Siliq and the approval of surgical platforms in the Bausch + Lomb optical unit offered incremental contributions to sales and earnings.